USD10
ANL delen
Info over Adlai NortyeAdlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
USD10
ANL delen
Info over Adlai NortyeAdlai Nortye Ltd is a clinical-stage biotechnology company focused on the discovery and development of cancer therapies for patients across the spectrum of tumor types. The company has a robust pipeline of drug candidates which includes buparlisib (AN2025), palupiprant (AN0025), and AN4005 in the clinical stage, and AN8025, AN9025, and AN1025 in the preclinical stage.
Statistieken
HANDELSVENSTER
Gesloten
OPENT OM
Onvoldoende gegevens
MARKTKAPITALISATIE
US$ 434,68 mln.
OPENINGSPRIJS
US$ 7,29
LAAG (1J)
US$ 0,8786
HOOG (1J)
US$ 12,09
LAAG (24u)
US$ 6,73
HOOG (24H)
US$ 7,73
VOLUME (24 uur)
US$ 251,92K
71,66%
Prijsgeschiedenis
Time | Price | Change |
|---|---|---|
Vandaag | US$ 7,29 | |
1 dag | US$ 7,45 | |
1 week | US$ 7,96 | |
1 maand | US$ 9,47 | |
1 jaar | US$ 2,33 |